HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dolnak, D. R. Search for Related Content PubMed PubMed Citation Articles by Dolnak, D. R.

Dr Dolnak is assistant medical director of California Clinical Trials and a clinical instructor in psychiatry at the University of California, San Diego.

Address correspondence to Douglas R. Dolnak, DO, California Clinical Trials, 3625 Russin Rd, Suite 100, San Diego, CA 92123. E-mail: doug.dolnak{at}cctrials.com.

Patients who have comorbid depression and anxiety present primary care physicians a diagnostic as well as a treatment challenge. Identifying these patients is imperative as they have a higher suicide rate than those with depression alone. Patients with major depressive disorder and other psychiatric illness (ie, comorbid generalized anxiety disorder) have a doublefold increase of suicide attempts than patients without comorbid depression. Other medical illnesses may also be comorbid with depression and anxiety. The key to accurate diagnosis is the physician's high index of suspicion, the use of appropriate rating scales for assessment, including patients' self-rating scales, and the team approach. Such scales are also helpful in monitoring progress of treatment and in empowering patients to take an active role in their treatment, which may include pharmacologic or nonpharmacologic treatment options. Patient education in which depression and anxiety are described as biological disorders or medical illnesses averts patients' embarrassment and increases compliance. Referral for psychotherapy also increases compliance. Discussion includes summaries of studies documenting the efficacy, advantages, and disadvantages of medications that have been approved by the US Food and Drug Administration for depression and anxiety. A few medications used off label are mentioned briefly.

This article has been cited by other articles:

				T. C. CYMET Sexually Activated or Transmitted? Questions About HPV. J Am Osteopath Assoc, July 1, 2006; 106(7): 423 - 423. [Full Text] [PDF]